A case of successful technology transfer ventures:
Research collaboration between University College Dublin (UCD) and Bio‑Medical Research (BMR) led to the development of a novel training device for the treatment of stress-induced urinary incontinence.
UCD licensed the technology to BMR, which validated the device in clinical trials, secured regulatory approval and launched it in Europe.
BMR established Atlantic Therapeutics as a spin-out company to secure investment to target the US market.
Atlantic Therapeutics, its flagship product, offers patients safe, non-invasive and cost-effective treatment for stress-induced urinary incontinence, improving the quality of lives.
Improving quality of life.
- In academy-industry collaborations, recognise all partners' needs and define incentives and criteria so that the company can act as the commercial partner.
- A joint ownership management agreement is necessary to facilitate later commercialisation if joint foreground IP is anticipated.
- The deal structure should always be benchmarked so that it is fair and reasonable and reflects industry norms.
- Agree on key development and commercial milestones early, to guide and facilitate market success, but be willing to amend as necessary.